secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001193125-23-016224
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase raises ~$10M via registered direct offering and private placement with warrants
--------------------------------------------------------------------------------

- Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.
- Issued unregistered warrants to purchase up to 11,627,908 shares at $0.75/share, exercisable for 5 years.
- Gross proceeds ~$10M; net proceeds for clinical trials, product development, and working capital.
- Terminated prior at-the-market equity distribution agreement with Piper Sandler (no sales made).
- H.C. Wainwright acted as exclusive placement agent; offering expected to close January 27, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/d369483d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-016224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer